A nurse is caring for a client who is taking azathioprine to treat rheumatoid arthritis. Which of the following laboratory values indicates an adverse effect of this medication?

Choice A Reason:
INR (International Normalized Ratio) is incorrect. INR is a measurement used to monitor the effects of anticoagulants like warfarin. It assesses the blood's ability to clot. Filgrastim does not directly affect INR levels, so monitoring INR would not provide information about the effectiveness of filgrastim in stimulating white blood cell production.
Choice B Reason:
BUN (Blood Urea Nitrogen) is incorrect. BUN levels primarily indicate kidney function and hydration status. They are not directly influenced by filgrastim treatment. Monitoring BUN is essential for assessing kidney function but does not reflect the effectiveness of filgrastim therapy in increasing white blood cell counts.
Choice C Reason:
WBC count is correct. Filgrastim is a medication that stimulates the production of white blood cells (WBCs), particularly neutrophils. Therefore, the key laboratory value to monitor for assessing the effectiveness of filgrastim therapy is the WBC count. An increase in the WBC count, particularly in the neutrophil count, signifies the intended therapeutic effect of filgrastim in boosting the immune system's response by increasing the production of these infection-fighting cells.
Choice D Reason:
Potassium level is incorrect. Potassium levels are crucial for heart and muscle function. While certain medications might affect potassium levels, filgrastim's primary action is on stimulating white blood cell production and does not directly impact potassium levels. Monitoring potassium levels is essential for overall health but does not specifically indicate the effectiveness of filgrastim treatment.

Choice A Reason:
Remove duplicate medications of different dosages from the reconciliation is incorrect. Removing duplicate medications with different dosages from the reconciliation is indeed essential. However, the primary focus during transfer is to compare the current medication list with the new regimen to avoid omissions or discrepancies in the transition process.
Choice B Reason:
Compare the current list of medications to medications the client will receive after transform is correct. Comparing the current list of medications, the client is taking to the medications they are expected to receive after transfer is crucial for ensuring a seamless transition of care. This process helps identify discrepancies, potential interactions, or changes in the medication regimen between settings, ensuring the continuity and accuracy of medication administration.
Choice C Reason:
Omit over-the-counter medications from the at-home medication list is incorrect. Over-the-counter medications should ideally be included in the medication reconciliation process to provide a comprehensive overview of all medications the client is taking, including potential interactions with prescribed medications.
Choice D Reason:
Include medications the client received in the acute setting but will no longer need after transfer is incorrect. The reconciliation process should aim to update the medication list to reflect the client's current and future medication needs accurately. Including medications, the client received in the acute setting but won't need after transfer might introduce unnecessary medications into the new regimen. These should be communicated but not included in the ongoing medication list.